Figure 2.

The immune microenvironment of prostate cancers. Myeloid-derived suppressor cells, increased adenosine concentrations, and immune checkpoints promote an immunologically cold phenotype. Monoclonal antibodies that target these proteins can help reduce immunosuppression. Cell-based such as sipuleucel-T and chimeric antigen receptor (CAR) T cell therapies can be engineered to target specific aspects of the tumor. Figure created via Adobe Inc. (2021). Adobe Illustrator version 25.2.3. Retrieved from https://adobe.com/products/illustrator (accessed on 11 April 2021).